EA201891085A1 - Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания - Google Patents
Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболеванияInfo
- Publication number
- EA201891085A1 EA201891085A1 EA201891085A EA201891085A EA201891085A1 EA 201891085 A1 EA201891085 A1 EA 201891085A1 EA 201891085 A EA201891085 A EA 201891085A EA 201891085 A EA201891085 A EA 201891085A EA 201891085 A1 EA201891085 A1 EA 201891085A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- disease
- ctc
- heterogeneity
- cells
- characterize
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6841—In situ hybridisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70589—CD45
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250422P | 2015-11-03 | 2015-11-03 | |
| PCT/US2016/059877 WO2017079139A1 (en) | 2015-11-03 | 2016-11-01 | Single cell genomic profiling of circulating tumor cells (ctcs) in metastatic disease to characterize disease heterogeneity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201891085A1 true EA201891085A1 (ru) | 2018-11-30 |
Family
ID=58662599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201891085A EA201891085A1 (ru) | 2015-11-03 | 2016-11-01 | Получение геномных профилей отдельных клеток для циркулирующих клеток опухолей (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20180321247A1 (enExample) |
| EP (1) | EP3371327B1 (enExample) |
| JP (1) | JP7043412B2 (enExample) |
| CN (2) | CN115341033A (enExample) |
| AU (2) | AU2016348401A1 (enExample) |
| CA (1) | CA3004150A1 (enExample) |
| EA (1) | EA201891085A1 (enExample) |
| IL (1) | IL259093A (enExample) |
| WO (1) | WO2017079139A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2491395B1 (en) | 2009-10-21 | 2015-09-16 | The Scripps Research Institute | Method of using non-rare cells to detect rare cells |
| WO2015112955A1 (en) | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EA201691682A1 (ru) | 2014-02-21 | 2017-02-28 | Эпик Сайенсиз, Инк. | Способы анализирования редких циркулирующих в крови клеток |
| JP7633173B2 (ja) * | 2019-03-28 | 2025-02-19 | ランドチ ダイアグノスティクス アーベー | ２型糖尿病リスク予測におけるフォリスタチンの使用 |
| US12412272B2 (en) | 2019-11-26 | 2025-09-09 | University Of Cincinnati | Characterizing intra-site tumor heterogeneity |
| CN117497044A (zh) * | 2022-03-09 | 2024-02-02 | 复旦大学 | 基于单细胞基因组拷贝数变异谱在制造细胞良恶性诊断试剂或检测试剂中的应用 |
| WO2024192141A1 (en) | 2023-03-13 | 2024-09-19 | Dana-Farber Cancer Institute, Inc. | Treatment of cancers having a drug-resistant mesenchymal cell state |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014047285A1 (en) * | 2012-09-19 | 2014-03-27 | Paraskevi Giannakakou | Identifying taxane sensitivity in prostate cancer patients |
| DK2981624T3 (da) | 2013-04-05 | 2020-03-02 | Myriad Genetics Inc | Fremgangsmåder til vurdering af homolog rekombinationsdeficiens og forudsigelse af respons på cancerbehandling |
| CN106062561B (zh) | 2013-09-30 | 2021-11-09 | 斯克利普斯研究院 | 为了监测前列腺癌患者中的肿瘤进化进行循环肿瘤细胞的基因型和表型分析 |
| US20150147339A1 (en) * | 2013-11-15 | 2015-05-28 | Psma Development Company, Llc | Biomarkers for psma targeted therapy for prostate cancer |
| US10745760B2 (en) * | 2014-01-17 | 2020-08-18 | University Health Network | Biopsy-driven genomic signature for prostate cancer prognosis |
| WO2015112955A1 (en) * | 2014-01-27 | 2015-07-30 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| EP3100052B1 (en) * | 2014-01-30 | 2021-03-10 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
-
2016
- 2016-11-01 WO PCT/US2016/059877 patent/WO2017079139A1/en not_active Ceased
- 2016-11-01 CN CN202210906018.2A patent/CN115341033A/zh active Pending
- 2016-11-01 US US15/773,154 patent/US20180321247A1/en not_active Abandoned
- 2016-11-01 AU AU2016348401A patent/AU2016348401A1/en not_active Abandoned
- 2016-11-01 CN CN201680078293.2A patent/CN108603233A/zh active Pending
- 2016-11-01 EP EP16862785.9A patent/EP3371327B1/en active Active
- 2016-11-01 EA EA201891085A patent/EA201891085A1/ru unknown
- 2016-11-01 JP JP2018543010A patent/JP7043412B2/ja active Active
- 2016-11-01 CA CA3004150A patent/CA3004150A1/en active Pending
-
2018
- 2018-05-02 IL IL259093A patent/IL259093A/en unknown
-
2021
- 2021-01-06 US US17/142,767 patent/US20210405055A1/en not_active Abandoned
-
2023
- 2023-01-24 AU AU2023200364A patent/AU2023200364A1/en not_active Abandoned
-
2024
- 2024-07-11 US US18/770,366 patent/US20250180564A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018534595A (ja) | 2018-11-22 |
| CN115341033A (zh) | 2022-11-15 |
| US20250180564A1 (en) | 2025-06-05 |
| JP7043412B2 (ja) | 2022-03-29 |
| AU2016348401A1 (en) | 2018-05-24 |
| EP3371327A4 (en) | 2019-07-03 |
| US20210405055A1 (en) | 2021-12-30 |
| US20180321247A1 (en) | 2018-11-08 |
| IL259093A (en) | 2018-06-28 |
| WO2017079139A1 (en) | 2017-05-11 |
| EP3371327B1 (en) | 2024-12-18 |
| AU2023200364A1 (en) | 2023-02-23 |
| CA3004150A1 (en) | 2017-05-11 |
| EP3371327A1 (en) | 2018-09-12 |
| CN108603233A (zh) | 2018-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201891571A1 (ru) | Геномное профилирование отдельных циркулирующих опухолевых клеток (ctc) при метастазирующем заболевании для характеризации гетерогенности заболевания | |
| Esmaeilsabzali et al. | Detection and isolation of circulating tumor cells: principles and methods | |
| EA201691352A1 (ru) | Диагностика рака легкого с помощью циркулирующих опухолевых клеток | |
| EA201691505A1 (ru) | Детектирование экспрессии простатического специфического мембранного антигена (psma) на циркулирующих опухолевых клетках (ctc) | |
| Liberko et al. | Essentials of circulating tumor cells for clinical research and practice | |
| EA201691496A1 (ru) | Диагностика биомаркеров рака предстательной железы с помощью циркулирующих опухолевых клеток | |
| MX390772B (es) | Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias. | |
| MX361058B (es) | Método para detectar células tumorales circulantes 5t4-positivas y métodos de diagnóstico de cáncer 5t4-positivo en un sujeto mamífero. | |
| EA201792497A1 (ru) | Антитела к gitr для диагностики злокачественной опухоли | |
| IL254639A0 (en) | Digital analysis of cancer cells moving in the bloodstream in blood samples | |
| WO2011112903A3 (en) | Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of breast cancer patients | |
| EA201691499A1 (ru) | Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям | |
| RU2013101996A (ru) | Диагностика и лечение рака молочной железы | |
| JP2020522697A5 (enExample) | ||
| EA201691497A1 (ru) | Способы детектирования и количественного определения имитаторов циркулирующих опухолевых клеток | |
| GB2523211A (en) | MCT protein inhibitor-related prognostic and therapeutic methods | |
| BR112016002709A2 (pt) | queratinas como biomarcadores para câncer cervical e sobrevivência | |
| EA201691168A1 (ru) | Способы исследования бета-глюкана | |
| WO2017053763A3 (en) | ANDROGEN RECEPTOR VARIANT 7 AS A BIOMARKER FOR TREATMENT SELECTION IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (mCRPC) | |
| Lopez-Munoz et al. | Markers of circulating breast cancer cells | |
| EA201690995A1 (ru) | Способы обнаружения и количественного анализа циркулирующих эндотелиальных клеток | |
| BR102015015096A2 (pt) | método de detecção in vitro de câncer de tireoide em um paciente, método in vitro de diferenciação entre câncer de tireoide e tecido de tireoide normal ou de lesões benignas de tireoide, uso de um conjunto de genes, método de obtenção de dados para direcionamento do tratamento do cancer de tireoide, kit laboratorial e dispositivo para classificar uma amostra biológica de glândula tireoide como maligna ou benigna | |
| Yao et al. | Clinicopathological features of pancreatic neuroendocrine neoplasms: a retrospective analysis of 64 cases | |
| RU2013140122A (ru) | Способ диагностики рака молочной железы | |
| EA201992876A1 (ru) | Способы определения терапии на основании характеристик отдельных клеток из циркулирующих опухолевых клеток (цок) при метастатическом заболевании |